Related Experiment Video

Updated: Jul 6, 2026

Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy
10:22

Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy

Published on: December 6, 2016

[The effect of valproic acid monotherapy on behavior and cognitive performance of children with idiopathic

A Schmidt1, J Darius, M Brosz

  • 1Institut für Neurobiologie, Otto-von-Geuricke-Universität, Magdeburg.

Zeitschrift Fur Kinder- Und Jugendpsychiatrie
|September 1, 1995
PubMed

Insights

Valproic acid (VPA) treatment in children with epilepsy may affect behavior and cognitive skills. Abnormal behavior and EEG changes correlate with VPA serum levels.

Area of Science:

  • Pediatric Neurology
  • Clinical Neurophysiology

Background:

  • Valproic acid (VPA) is a key epilepsy treatment, particularly in children, often chosen for its perceived minimal adverse effects on cognition.
  • Existing literature presents conflicting findings on VPA's impact on behavior, cognitive function, and EEG parameters in pediatric populations.

Purpose of the Study:

  • To investigate the effects of VPA monotherapy on behavioral components, cognitive efficiency, and evoked potentials in children with epilepsy.
  • To compare these outcomes with age-matched healthy controls.
  • To analyze the correlation between VPA serum levels and observed effects.

Main Methods:

  • Assessed behavioral components (attention, concentration, inhibitory control) and cognitive efficiency (reaction time, learning, retention) in 19 children (6-14 years) with idiopathic generalized epilepsy on VPA monotherapy.
  • Measured evoked potentials and analyzed serum VPA and metabolite levels prior to psychophysiological assessments.
  • Compared results with a healthy control group.

Main Results:

  • Children with epilepsy on VPA showed significant differences in all assessed behavioral and cognitive domains compared to controls.
  • Abnormal behaviors, including attention deficits and impulsivity, were observed.
  • Evoked potential changes were significant and correlated with VPA serum levels and metabolites.

Conclusions:

  • VPA monotherapy in children with epilepsy is associated with notable behavioral and cognitive alterations.
  • Serum VPA levels and specific metabolites appear to correlate with these observed changes and evoked potential abnormalities.
  • Further research is warranted to understand the mechanisms and clinical implications of these findings.

More Related Videos

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice07:01

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

Electromagnetic Source Imaging in Presurgical Evaluation of Children with Drug-Resistant Epilepsy09:57

Electromagnetic Source Imaging in Presurgical Evaluation of Children with Drug-Resistant Epilepsy

Published on: September 20, 2024

Related Concept Videos

Mania and Antimanic Drugs: Overview01:24

Mania and Antimanic Drugs: Overview

Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as a...
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...